Using AI to De-Risk Rare Disease Drug Development
Tim Guilliams, co-founder and CEO of Healx, discusses the origin of the company, its lead asset in development for neurofibromatosis type 1, and how he views the company’s progress to date.
Tim Guilliams, co-founder and CEO of Healx, discusses the origin of the company, its lead asset in development for neurofibromatosis type 1, and how he views the company’s progress to date.